A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Namilumab (Primary)
- Indications Pulmonary sarcoidosis
- Focus Therapeutic Use
- Acronyms RESOLVE-Lung
- Sponsors Kinevant Sciences GmbH
- 20 Aug 2024 Planned End Date changed from 1 Jun 2025 to 1 Jul 2025.
- 26 Apr 2024 Planned End Date changed from 1 Jan 2025 to 1 Jun 2025.
- 26 Apr 2024 Planned primary completion date changed from 1 May 2024 to 1 Dec 2024.